Literature DB >> 26516107

Mortality and cardiovascular disease outcomes among 740 patients with new-onset Type 2 diabetes detected by screening or clinically diagnosed in general practice.

S P O Jansson1,2, D K G Andersson1, K Svärdsudd1.   

Abstract

AIM: Screening for Type 2 diabetes among people at high risk is recommended by many organizations. The aim of this study was to analyse all-cause mortality and cardiovascular disease (CVD) outcomes in patients with Type 2 diabetes detected by screening or diagnosed clinically.
METHODS: A diabetes register was established at the primary healthcare centre in Laxå, Sweden beginning in 1972. The register was based on data from clinical records with information on medical treatment and laboratory data, as well as all-cause mortality, CVD, myocardial infarction and stroke events from national registers until 31 December 2013. A total of 740 patients with new-onset Type 2 diabetes were registered between 1972 and 2001. In addition, an opportunistic diabetes-screening programme involving people aged 35-79 years started in 1983 and was repeated onwards in 5-year cycles.
RESULTS: Baseline characteristics showed a significantly higher CVD risk, mainly depending on more prevalent CVD events in the screened compared with the clinically detected group (propensity score 0.59 vs. 0.46, P < 0.0001). After mean follow-up periods of 12.9 and 13.6 years for screening detected vs. clinically detected patients, respectively, hazard ratios were as follows: all-cause mortality, 0.99 (P = 0.89); CVD, 1.17 (P = 0.10); myocardial infarction, 1.08 (P = 0.49); and stroke, 1.03 (P = 0.83).
CONCLUSIONS: No reduction in total mortality or CVD outcomes was found in patients with Type 2 diabetes that was detected by screening compared with those diagnosed clinically.
© 2015 The Authors. Diabetic Medicine © 2015 Diabetes UK.

Entities:  

Mesh:

Year:  2015        PMID: 26516107     DOI: 10.1111/dme.13019

Source DB:  PubMed          Journal:  Diabet Med        ISSN: 0742-3071            Impact factor:   4.359


  5 in total

1.  Prevalence of diabetic retinopathy in screening-detected diabetes mellitus: results from the Gutenberg Health Study (GHS).

Authors:  Katharina A Ponto; Jochem Koenig; Tunde Peto; Julia Lamparter; Philipp Raum; Philipp S Wild; Karl J Lackner; Norbert Pfeiffer; Alireza Mirshahi
Journal:  Diabetologia       Date:  2016-06-17       Impact factor: 10.122

2.  Myricetin: a potent approach for the treatment of type 2 diabetes as a natural class B GPCR agonist.

Authors:  Ying Li; Xuemin Zheng; Xiulin Yi; Changxiao Liu; Dexin Kong; Jianning Zhang; Min Gong
Journal:  FASEB J       Date:  2017-03-07       Impact factor: 5.191

3.  Screening for type 2 diabetes: do screen-detected cases fare better?

Authors:  Adina L Feldman; Simon J Griffin; Eva Fhärm; Margareta Norberg; Patrik Wennberg; Lars Weinehall; Olov Rolandsson
Journal:  Diabetologia       Date:  2017-08-23       Impact factor: 10.122

4.  Short-term progression of cardiometabolic risk factors in relation to age at type 2 diabetes diagnosis: a longitudinal observational study of 100,606 individuals from the Swedish National Diabetes Register.

Authors:  Andri O Steinarsson; Araz Rawshani; Soffia Gudbjörnsdottir; Stefan Franzén; Ann-Marie Svensson; Naveed Sattar
Journal:  Diabetologia       Date:  2018-01-09       Impact factor: 10.122

5.  Education, immigration and income as risk factors for hemoglobin A1c >70 mmol/mol when diagnosed with type 2 diabetes or latent autoimmune diabetes in adult: a population-based cohort study.

Authors:  Mats Martinell; Ronnie Pingel; Johan Hallqvist; Mozhgan Dorkhan; Leif Groop; Anders Rosengren; Petter Storm; Jan Stålhammar
Journal:  BMJ Open Diabetes Res Care       Date:  2017-05-08
  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.